CVS · News · 20260805N
Guidance and Outlook
CVS HEALTH Corp · 2026-08-05 · Importance 66 · Surprise 84 · In source text
CVS Health raised its full-year 2026 GAAP diluted EPS guidance to $6.84-$7.04 from $6.24-$6.44. Adjusted EPS guidance increased to $7.90-$8.10 from $7.30-$7.50, above the approximately $7.45 analyst consensus. Operating cash-flow guidance increased to at least $11.5 billion from at least $9.5 billion, while year-to-date operating cash flow was $10.6 billion through June 30, 2026. The higher outlook reflects Aetna’s improving medical-cost performance, although 2027 risks include 340B changes, Caremark membership declines, and elevated costs.
Key facts
- Raised full-year 2026 GAAP diluted EPS guidance range to $6.84 to $7.04 from $6.24 to $6.44. source
- Raised full-year 2026 Adjusted EPS guidance range to $7.90 to $8.10 from $7.30 to $7.50. source
- CNBC reported that CVS blew past second-quarter earnings and revenue estimates and raised its 2026 guidance as Aetna shows signs of recovery. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | committed | — | Raised full-year 2026 GAAP diluted EPS guidance range to $6.84 to $7.04 from $6.24 to $6.44. |
| net_income | positive | committed | — | Raised full-year 2026 Adjusted EPS guidance range to $7.90 to $8.10 from $7.30 to $7.50. |